Page last updated: 2024-11-12

panepophenanthrin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

panepophenanthrin: from a mushroom strain, an inhibitor of the ubiquitin-activating enzyme; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10432257
CHEMBL ID2046774
MeSH IDM0442898

Synonyms (12)

Synonym
panepophenanthrin
bdbm50387036
CHEMBL2046774 ,
panepophenanthrine
(1s,2s,3r,4s,6s,10s,13r,14s,16s,17r,18s)-3,13,17-trihydroxy-18-[(e)-3-hydroxy-3-methylbut-1-enyl]-11,11-dimethyl-5,12,15-trioxahexacyclo[8.7.1.02,8.04,6.013,18.014,16]octadec-8-en-7-one
(1as,1br,3as,5as,6as,7r,7as,7bs,7cs,8r,8as)-1a,1b,3,3a,5a,6a,7,7a,7b,7c,8,8a-dodecahydro-1b,7,8-trihydroxy-7c-((1e)-3-hydroxy-3-methyl-1-buten-1-yl)-3,3-dimethyl-5h-bisoxireno(2,3:6,7)phenanthro(1,10-bc)furan-5-one
5h-bisoxireno(2,3:6,7)phenanthro(1,10-bc)furan-5-one, 1a,1b,3,3a,5a,6a,7,7a,7b,7c,8,8a-dodecahydro-1b,7,8-trihydroxy-7c-((1e)-3-hydroxy-3-methyl-1-buten-1-yl)-3,3-dimethyl-, (1as,1br,3as,5as,6as,7r,7as,7bs,7cs,8r,8as)-
791vps8i0j ,
(+)-panepophenanthrin
409064-57-9
panepophenanthrin [mi]
unii-791vps8i0j
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
DNA damage responseUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
protein ubiquitinationUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
ubiquitin-dependent protein catabolic processUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
RNA bindingUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
ubiquitin activating enzyme activityUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
protein bindingUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
ATP bindingUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
heterochromatinUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
lysosomal membraneUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
endosome membraneUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
desmosomeUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
rough endoplasmic reticulum membraneUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
nucleusUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
nucleoplasmUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
cytoplasmUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
mitochondrionUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
cytosolUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
extracellular exosomeUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
nucleusUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
cytoplasmUbiquitin-like modifier-activating enzyme 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID670507Inhibition of ubiquitin-activating enzyme E12012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Hyrtioreticulins A-E, indole alkaloids inhibiting the ubiquitin-activating enzyme, from the marine sponge Hyrtios reticulatus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]